OBJECTIVE: Defibrotide is a heterogenous mixture of polyanionic oligonucleotides currently approved for treatment of transplant-associated venoocclusive disease. While defibrotide has a known role in limiting endothelial cell activation, some studies have also demonstrated anti-leukocyte properties. In a recent study, we found that neutrophil extracellular traps (NETs) play a role in the thrombotic complications of antiphospholipid syndrome (APS). In the present study, we investigated the hypothesis that defibrotide might act to mitigate APS-relevant NET formation in vitro and in mouse models. METHODS: We used in vitro assays and a mouse model to determine the mechanisms by which defibrotide inhibits NET formation and venous thrombosis in APS. RESULTS: At doses ranging from 1 to 10 μg/ml, defibrotide significantly suppressed NET formation from control neutrophils stimulated with IgG isolated from patients with APS. Defibrotide increased levels of intracellular cyclic AMP in neutrophils, and its suppressive effects on NET formation were mitigated by blocking adenosine A2A receptor or by inhibiting the cyclic AMP-dependent kinase protein kinase A. Defibrotide at doses ranging from 15 to 150 mg/kg/day inhibited NET formation and venous thrombosis in a model of antiphospholipid antibody-accelerated thrombosis-an effect that was reduced in adenosine A2A receptor-knockout mice. CONCLUSION: This study is the first to demonstrate mechanisms by which defibrotide counteracts neutrophil-mediated thrombotic inflammation inherent to APS.
OBJECTIVE: Defibrotide is a heterogenous mixture of polyanionic oligonucleotides currently approved for treatment of transplant-associated venoocclusive disease. While defibrotide has a known role in limiting endothelial cell activation, some studies have also demonstrated anti-leukocyte properties. In a recent study, we found that neutrophil extracellular traps (NETs) play a role in the thrombotic complications of antiphospholipid syndrome (APS). In the present study, we investigated the hypothesis that defibrotide might act to mitigate APS-relevant NET formation in vitro and in mouse models. METHODS: We used in vitro assays and a mouse model to determine the mechanisms by which defibrotide inhibits NET formation and venous thrombosis in APS. RESULTS: At doses ranging from 1 to 10 μg/ml, defibrotide significantly suppressed NET formation from control neutrophils stimulated with IgG isolated from patients with APS. Defibrotide increased levels of intracellular cyclic AMP in neutrophils, and its suppressive effects on NET formation were mitigated by blocking adenosine A2A receptor or by inhibiting the cyclic AMP-dependent kinase protein kinase A. Defibrotide at doses ranging from 15 to 150 mg/kg/day inhibited NET formation and venous thrombosis in a model of antiphospholipid antibody-accelerated thrombosis-an effect that was reduced in adenosine A2A receptor-knockout mice. CONCLUSION: This study is the first to demonstrate mechanisms by which defibrotide counteracts neutrophil-mediated thrombotic inflammation inherent to APS.
Authors: Robert C Grenn; Srilakshmi Yalavarthi; Alex A Gandhi; Nayef M Kazzaz; Carlos Núñez-Álvarez; Diego Hernández-Ramírez; Antonio R Cabral; W Joseph McCune; Paula L Bockenstedt; Jason S Knight Journal: Ann Rheum Dis Date: 2016-07-18 Impact factor: 19.103
Authors: Gautam Sule; William J Kelley; Kelsey Gockman; Srilakshmi Yalavarthi; Andrew P Vreede; Alison L Banka; Paula L Bockenstedt; Omolola Eniola-Adefeso; Jason S Knight Journal: Arthritis Rheumatol Date: 2020-01 Impact factor: 10.995
Authors: F L Pasini; C Frigerio; P L Capecchi; L Ceccatelli; G L Messa; M Franchi; T Di Perri Journal: Semin Thromb Hemost Date: 1996 Impact factor: 4.180
Authors: Tobias A Fuchs; Alexander Brill; Daniel Duerschmied; Daphne Schatzberg; Marc Monestier; Daniel D Myers; Shirley K Wrobleski; Thomas W Wakefield; John H Hartwig; Denisa D Wagner Journal: Proc Natl Acad Sci U S A Date: 2010-08-23 Impact factor: 11.205
Authors: He Meng; Srilakshmi Yalavarthi; Yogendra Kanthi; Levi F Mazza; Megan A Elfline; Catherine E Luke; David J Pinsky; Peter K Henke; Jason S Knight Journal: Arthritis Rheumatol Date: 2017-03 Impact factor: 10.995
Authors: P G Richardson; A D Elias; A Krishnan; C Wheeler; R Nath; D Hoppensteadt; N M Kinchla; D Neuberg; E K Waller; J H Antin; R Soiffer; J Vredenburgh; M Lill; A E Woolfrey; S I Bearman; M Iacobelli; J Fareed; E C Guinan Journal: Blood Date: 1998-08-01 Impact factor: 22.113
Authors: Ramadan A Ali; Alex A Gandhi; Lipeng Dai; Julia Weiner; Shanea K Estes; Srilakshmi Yalavarthi; Kelsey Gockman; Duxin Sun; Jason S Knight Journal: JCI Insight Date: 2021-02-08